Boehringer Ingelheim has introduced Aservo EquiHaler to the UK and Irish markets, a ciclesonide inhalation solution designed to allow medication to be inhaled deep into the lungs of horses suffering severe asthma, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks often associated with systemic corticosteroids. This first of a kind product is made from 50% recycled materials and does not use a propellant.
“ The launch is a prime example of leveraging innovation efforts of both our human and animal businesses“
Head of Business Unit Equine UK & Ireland, Marc Laemmer, said: “It’s another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation. We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available. The launch is a prime example of leveraging innovation efforts of both our human and animal businesses. This has been a strength of ours and I’m excited that we are continuing to further increase the delivery of innovative solutions for horse owners and vets.”